Ovid Therapeutics Inc.
OVID · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 44.4% | -73.9% | -99.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | $0 |
| % Margin | -10,207.1% | -14,544.1% | -3,604.5% | 59.7% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -4,670.1% | -13,351.8% | -3,604.7% | 58.9% |
| EPS Diluted | -0.37 | -0.74 | -0.77 | 1.76 |
| % Growth | 50% | 3.9% | -143.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |